Navigation Links
Centrix Pharmaceutical Announces Clofera(TM), a Unique Antitussive and Nasal Decongestant for the Temporary Relief of Cough and Nasal Congestion
Date:8/14/2009

BIRMINGHAM, Ala., Aug. 14 /PRNewswire/ -- Centrix Pharmaceutical, Inc., a privately-held specialty pharmaceutical company focused on Pediatrics and Women's Health, announced plans to commercially launch Clofera(TM) for the temporary relief of cough and nasal congestion.

Clofera(TM) is indicated for the temporary relief of cough and nasal congestion due to the common cold, hay fever, or other upper respiratory allergies. Clofera(TM) contains a non-narcotic antitussive, chlophedianol hydrochloride, in addition to nasal decongestant, pseudoephedrine hydrochloride. The product is specifically formulated without dyes, sugar, alcohol or gluten to meet particular consumer needs and address patient sensitivities. Clofera(TM) is expected to release during the beginning of the fourth quarter.

"We are pleased to introduce Clofera to temporarily control the cough reflex, therefore reducing the intensity of coughing with a product that is free of narcotic effects. Clofera provides physicians with another therapeutic option in the management of cough and congestion associated with allergic rhinitis or the common cold. The release of Clofera further compliments our goal to develop and expand the Centrix specialty portfolio," stated John R. (Bob) Booth, President and CEO of Centrix Pharmaceutical.

About Clofera(TM)

Clofera(TM) temporarily controls the cough reflex, temporarily relieves nasal congestion, swollen nasal passages, sinus congestion and pressure. Clofera(TM) should not be used in patients taking monoamine oxidase inhibitors or with known hypersensitivity to any of the components of the product. Patients with a chronic cough, asthma, emphysema, mucus production, heart disease, high blood pressure, thyroid disease, diabetes, or enlarged prostate should consult physician before use. Recommended dosage should not be exceeded. Clofera(TM) contains no dextromethorphan, antihistamines, sugar, alcohol, or dyes and is gluten free. Clofera(TM) will be available in grape flavor.

About Centrix Pharmaceutical, Inc.

Centrix Pharmaceutical is a privately-held specialty pharmaceutical company focused in Pediatrics and Women's Health. Headquartered in Birmingham, AL, the Company's products are marketed by its dedicated sales force in the United States. For more information about Centrix Pharmaceutical, Inc. visit www.cenrx.com.


'/>"/>
SOURCE Centrix Pharmaceutical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CareCentrix Adds to Senior Leadership Team
2. HeartCentrix Informatics Solution from Cardiac Science Now Certified with Allscripts Electronic Health Records
3. Gentiva(R) Health Services Promotes Boelsen to Senior Vice President, CareCentrix(R)
4. Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Henry Schein Medical Systems MicroMD(R) EMR 5.0
5. Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies
6. WuXi PharmaTech Selected as One of the Top Ten Employer for New College Graduates in Pharmaceutical Industry in 2009
7. Hisamitsu Pharmaceutical Announces Expiration of HSR Waiting Period for Its Proposed Acquisition of Noven Pharmaceuticals
8. Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record of Quality
9. Thomson Reuters Invites You to the First Latin American Forum Covering the Pharmaceutical Industry
10. Sun Pharmaceutical to File HSR Application for Taro Tender Offer
11. Endo Pharmaceuticals Announces Resignation of Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... An April 24th article on Yahoo! Beauty discusses ... with the help of a weight loss surgery. The woman, declaring “I will not hate ... been left following her dramatic weight loss. Dr. Feiz & Associates notes that, while it ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... its new partnership with the Home Care Association of America (HCAOA). This agreement ... Private Duty Accreditation services, as well as discounts on Accreditation University (AU) educational ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage ... unmet medical needs, today announced that it will ... development program, based on its proprietary self-delivering RNAi ... (SID) 76 th Annual Meeting.  The SID ... relevant to skin health and disease through education, ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: